Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa
Photo by Robina Weermeijer on Unsplash

Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa
ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer
source: pixabay.com

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Over 50% of non-small cell lung cancer patients (NSCLC) will experience a recurrence after surgery. The cancer recurs even after adjuvant chemotherapy after major surgery. ALINA’s data show that Alecensa…

Continue Reading ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer
Non-small Cell Lung Cancer: Alecensa Achieved Disease-Free Survival in Phase III Interim Analysis
source: shutterstock.com

Non-small Cell Lung Cancer: Alecensa Achieved Disease-Free Survival in Phase III Interim Analysis

   Currently, almost half the patients with non-small cell lung cancer (NSCLC) will see their disease return despite aggressive chemotherapy treatment (adjuvant surgery). Adjuvant therapy is treatment that is given…

Continue Reading Non-small Cell Lung Cancer: Alecensa Achieved Disease-Free Survival in Phase III Interim Analysis